Testing SIBP-A18 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug, SIBP-A18, for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers that have a protein called CLDN18.2.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have an advanced solid tumor that has come back or not responded to standard treatments, or you cannot have standard treatments.
- For some groups, your tumor must have a protein called CLDN18.2, found in certain stomach, pancreatic, or bile duct cancers.
- You must be able to provide a tumor sample (old biopsy or new one) from the past 2 years.
- You must have at least one tumor that can be measured on scans and have not received a type of drug called topoisomerase I inhibitor before.
- You must be in generally good health, with good blood counts and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SIBP-A17 for advanced solid tumors that have not responded to other treatments. It focuses on tumors that have a protein called HER2, and the goal is to see if the drug is safe and effective.
This Phase 1 study tests SKB315 to treat advanced solid tumors, with special focus on stomach/gastroesophageal junction cancer that has high CLDN18.2 in tumor tissue. It may help you if standard treatments have not worked or are not available, though early-phase studies mainly look at safety and the best way to dose.
This Phase 1 study tests SG1906, a new investigational drug, in people with certain advanced solid tumors that test positive for CLDN18.2. The goal is to see whether the drug is safe and to learn how well it may work in shrinking tumors or controlling the disease.
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
This trial is testing an investigational drug called SIBP-A19 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug called SIBP-A13 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective for different cancer types, including lung, breast, and head and neck cancers.
Hear when a new Solid Tumor Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.